A Phase III, multicenter, randomized study of atezolizumab (anti-PD-L1 antibody) in combination with enzalutamide versus enzalutamide alone in patients with metastatic castration resistant prostate cancer after failure of an androgen synthesis inhibitor and failure of, ineligibility for, or refusal of a taxane regimen CO39385